期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 122, 期 11, 页码 3931-3942出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI63170
关键词
-
资金
- NIH [RO1DK56223, RO1DK62324, P01HL073361]
- Genzyme (Genzyme Renal Innovations Program)
- American Heart Association [0835258N]
DC-mediated NKT cell activation is critical in initiating the immune response following kidney ischemia/reperfusion injury (IRI), which mimics human acute kidney injury (AKI). Adenosine is an important antiinflammatory molecule in tissue inflammation, and adenosine 2A receptor (A(2A)R) agonists protect kidneys from IRI through their actions on leukocytes. In this study, we showed that mice with A(2A)R-deficient DCs are more susceptible to kidney IRI and are not protected from injury by A(2A)R agonists. In addition, administration of DCs treated ex vivo with an A(2A)R agonist protected the kidneys of WT mice from IRI by suppressing NKT production of IFN-gamma and by regulating DC costimulatory molecules that are important for NKT cell activation. A(2A)R agonists had no effect on DC antigen presentation or on Tregs. We conclude that ex vivo A(2A)R-induced tolerized DCs suppress NKT cell activation in vivo and provide a unique and potent cell-based strategy to attenuate organ IRI.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据